Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Mid Cap
Health Score : 7.91Gland Pharma Ltd. presents a picture of exceptional financial strength, marked by outstanding profitability and impressive growth. The company is extremely stable, operating with almost no debt, which makes it highly resilient to financial shocks. It is rapidly expanding its sales, profits, and assets, indicating a successful business strategy and strong market demand. Shareholders benefit from high earnings, a strong asset backing per share, and attractive dividends. However, there is a significant contrast in its operational efficiency. The company struggles to use its assets effectively to generate sales and is slow in selling inventory and collecting payments. This inefficiency is a notable weakness in an otherwise stellar financial profile. Looking ahead, while growth and profitability are expected to remain strong, the key challenge for the company will be translating its significant investments into more productive and efficient operations.
Health Score : 7.91Gland Pharma Ltd. presents a picture of exceptional financial strength, marked by outstanding profitability and impressive growth. The company is extremely stable, operating with almost no debt, which makes it highly resilient to financial shocks. It is rapidly expanding its sales, profits, and assets, indicating a successful business strategy and strong market demand. Shareholders benefit from high earnings, a strong asset backing per share, and attractive dividends. However, there is a significant contrast in its operational efficiency. The company struggles to use its assets effectively to generate sales and is slow in selling inventory and collecting payments. This inefficiency is a notable weakness in an otherwise stellar financial profile. Looking ahead, while growth and profitability are expected to remain strong, the key challenge for the company will be translating its significant investments into more productive and efficient operations.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
36.45
Industry Median
30.91
Mid Cap Median
44.19
P/E RATIO
46.11
P/B RATIO
4.57
Industry Median
3.69
Mid Cap Median
6.64
P/S RATIO
7.38
Industry Median
3.74
Mid Cap Median
6.84
Others
PEG RATIO
49.58
EV/EBITDA RATIO
22.99
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2875 as on Sep 1, 2026.
Growth Score : 10.00The company is in a phase of exceptional growth. It is expanding its revenue, profits, and asset base at an outstanding rate. This rapid expansion across all key growth indicators points to strong market positioning, high demand for its products or services, and a successful strategy for scaling the business. This robust growth is a major strength and a key driver of value for the company.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 27.09 | -17.63 | 56.28 | -0.86 | 14.51 |
| Operating Profit Growth Rate | 15.98 | -32.12 | 30.05 | -4.8 | 28.45 |
| Earnings Per Share (EPS) Growth | 21.02 | -35.7 | -1.1 | -9.59 | 47.05 |
| Asset Growth Rate | 20.6 | 12.05 | 20.88 | 5.3 | 11.98 |
| Net Income Growth Rate | 21.56 | -35.56 | -1.15 | -9.46 | 46.92 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 49.00 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 2 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 3 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 4 | Neuland Laboratories Ltd | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 5 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 6 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 7 | Alembic Pharmaceuticals Ltd | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 9 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 10 | ERIS Lifesciences Ltd | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 11 | Ipca Laboratories Ltd | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
| 12 | Piramal Pharma Ltd | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 13 | Jubilant Pharmova Ltd | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 14 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 15 | Wockhardt Ltd | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 16 | Pfizer Ltd | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤3rd Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
Gland Pharma Ltd is a leading Indian pharmaceutical company specializing in sterile injectables. Operating on a B2B model, it develops, manufactures, and markets complex injectables and biosimilars for regulated markets globally, including the US, Europe, and Canada. The company is known for its strong R&D capabilities and high-quality manufacturing facilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Gland Pharma Ltd's P/E ratio (TTM) is 36.45, compared to the industry median of 30.91 and large cap median of 44.19.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Gland Pharma Ltd's P/B ratio is 4.57, compared to the industry median of 3.69 and large cap median of 6.64.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Gland Pharma Ltd's P/S ratio is 7.38, compared to the industry median of 3.74 and large cap median of 6.84.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Gland Pharma Ltd's PEG ratio is 49.58.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Gland Pharma Ltd's EV/EBITDA ratio is 22.99.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Gland Pharma Ltd's ROE is 9.92%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Gland Pharma Ltd's ROA is 13.03%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Gland Pharma Ltd's ROCE is 15%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Gland Pharma Ltd's operating margin is 25.35%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Gland Pharma Ltd's net margin is 15.97%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Gland Pharma Ltd's current ratio is 3.76.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Gland Pharma Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Gland Pharma Ltd's interest coverage ratio is 45.39.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Gland Pharma Ltd's DPS is ₹19.95.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Gland Pharma Ltd's EPS is 47.05.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹2875. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1978
Headquarters: Hyderabad, Telangana
Core Offerings: Sterile Injectable Formulations, Biosimilars, Oncology products, Contract Development and Manufacturing (CDMO), Active Pharmaceutical Ingredients (APIs)
Stock Listing: NSE (GLAND), BSE (543245)
Promoter: Fosun Pharma Industrial Pte. Ltd. (part of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.)
Gland Pharma was incorporated in 1978 by P.V.N. Raju, commencing commercial operations in 1986. It secured US FDA approval for its first injectable manufacturing facility in 2003, marking its entry into regulated markets. In 2013, the company diversified into the biosimilar business. A significant milestone occurred in 2017 with its acquisition by Fosun Pharma Industrial Pte. Ltd. Gland Pharma successfully launched its Initial Public Offering (IPO) in 2020, becoming a publicly listed entity on Indian stock exchanges. In 2023, it completed the acquisition of Cenexi, a European CDMO group, further strengthening its global footprint.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Finished Formulations (Injectables) | 90-95% (approx) | N/A (company-wide margins are strong) |
| Active Pharmaceutical Ingredients (APIs) | 5-8% (approx) | Operating Profit |
| Contract Manufacturing & Development Services (CDMO) | Growing (part of Finished Formulations) | Operating Profit |
Finished Formulations (Injectables): This is Gland Pharma's core business, focusing on developing, manufacturing, and marketing complex sterile injectables. Products include small volume parenterals, ophthalmic, suspensions, and long-acting injectables for various therapeutic areas like oncology, anti-infectives, and cardiovascular diseases. The company caters primarily to regulated markets such as the US, Europe, Canada, and Australia.
Active Pharmaceutical Ingredients (APIs): Gland Pharma also manufactures and supplies Active Pharmaceutical Ingredients, which are the biologically active components of a drug. This segment supports its own formulations and external customers.
Contract Manufacturing & Development Services (CDMO): The company offers CDMO services, leveraging its R&D and manufacturing expertise to develop and produce sterile injectables for other pharmaceutical companies. The acquisition of Cenexi significantly expanded its CDMO capabilities, especially in Europe.
Srinivas Sadu (Managing Director & CEO): A seasoned professional with over two decades of experience in the pharmaceutical industry, he has been instrumental in Gland Pharma's growth and operational excellence, having held various leadership positions within the company prior to his current role.
Gland Pharma International Pte. Ltd., Singapore
Gland Pharma US Inc., USA
Gland Pharma FZE, UAE
Cenexi (France & Belgium)
Gland Pharma Australia Pty Ltd
Vitane Biologics Private Limited, India
In 2023, Gland Pharma completed the acquisition of Cenexi, a leading European CDMO group, significantly enhancing its manufacturing capabilities and geographical footprint in Europe. Also in 2023, the company acquired Vitane Biologics Private Limited, expanding its presence in the biologics CDMO space.
The Gland Pharma Ltd share price today is ₹2875 on NSE (GLAND), as of 26 Sept 2026.
As of 25 Sept 2026, Gland Pharma Ltd share price is ₹2875, with previous close ₹2875. Today's range is ₹2875 to ₹2875. The 52-week range is ₹1573.60 to ₹3042.
As of today, Gland Pharma Ltd's market cap is ₹47,437.5 crore (Large Cap).
Gland Pharma Ltd's current P/E ratio is 36.45, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 40.
Gland Pharma Ltd's current P/B ratio is 4.57.
Gland Pharma Ltd's current dividend yield is 0.69%. Last dividend of ₹6.00 per share was declared on 12-Feb-2024.
Gland Pharma Ltd's EPS (TTM) is ₹47.05.
Gland Pharma Ltd is a leading Indian pharmaceutical company specializing in sterile injectables. Operating on a B2B model, it develops, manufactures, and markets complex injectables and biosimilars for regulated markets globally, including the US, Europe, and Canada. The company is known for its strong R&D capabilities and high-quality manufacturing facilities.
Gland Pharma Ltd is promoted by Fosun Pharma Industrial Pte. Ltd. (part of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.), holding 51.83% as of 25 Sept 2026.
Gland Pharma Ltd is listed on NSE (GLAND) and BSE (543245). Its next quarterly results are expected on Mid-August 2024 (for Q1 FY25).
